NCT05654831View on ClinicalTrials.gov

FTIH of ECC5004 in Healthy and Diabetic Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Placebo

Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.

DRUG

ECC5004

ECC5004 will be administered as oral tablet(s) during each dosing day.

Trial Locations (1)

92801

Eccogene Investigational Site, Anaheim

Sponsors

Lead Sponsor

Eccogene
All Listed Sponsors
lead

Eccogene

INDUSTRY

NCT05654831 - FTIH of ECC5004 in Healthy and Diabetic Participants | Biotech Hunter | Biotech Hunter